PharMerica upgraded to Outperform from Neutral at Credit Suisse Credit Suisse upgraded PharMerica citing improving fundamentals, capital deployment opportunities, and valuation. Price target raised to $30 from $19.
PharMerica announces wholesale agreement with Cardinal Health PharMerica Corporation (PMC) announced that it has entered into a new wholesale drug distribution agreement with Cardinal Health (CAH). The new agreement will take effect on April 1 and extend through June 2018. As part of the agreement, Cardinal Health will assume responsibility for the sourcing and distribution of branded and generic pharmaceuticals for PharMerica.